Literature DB >> 2266376

Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease.

N Wolfe1, D I Katz, M L Albert, A Almozlino, R Durso, M C Smith, L Volicer.   

Abstract

A distinct pattern of neuropsychological deficits was associated with low homovanillic acid (HVA) in the cerebrospinal fluid of 21 patients with: Alzheimer's disease (9), Parkinson's disease (8) and major depressive disorders (4). Regardless of clinical diagnosis, patients with low HVA were slower on a test of efficiency of processing timed information, and showed greater benefit from semantic structure on a verbal fluency task than patients with high HVA. However, low HVA subjects were not significantly impaired on confrontation naming (Boston Naming Test). Across three diagnostic groups, patients with lower HVA also tended to have more extrapyramidal motor signs and were significantly more depressed. These results demonstrate a significant relationship between specific neuro-behavioural deficits and dopaminergic activity which cuts across traditional diagnostic categories.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2266376      PMCID: PMC488258          DOI: 10.1136/jnnp.53.10.915

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  Slowed information processing in multiple sclerosis.

Authors:  I Litvan; J Grafman; P Vendrell; J M Martinez
Journal:  Arch Neurol       Date:  1988-03

2.  Cognitive fluctuations associated with on-off phenomenon in Parkinson disease.

Authors:  D Delis; L Direnfeld; M P Alexander; E Kaplan
Journal:  Neurology       Date:  1982-09       Impact factor: 9.910

3.  Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study.

Authors:  D Rogers; A J Lees; E Smith; M Trimble; G M Stern
Journal:  Brain       Date:  1987-06       Impact factor: 13.501

4.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

5.  Cognitive deficits in the early stages of Parkinson's disease.

Authors:  A J Lees; E Smith
Journal:  Brain       Date:  1983-06       Impact factor: 13.501

6.  High speed memory scanning in parkinsonism.

Authors:  R S Wilson; A W Kaszniak; H L Klawans; D C Garron
Journal:  Cortex       Date:  1980-03       Impact factor: 4.027

7.  Learning deficit in Parkinson's disease. Comparison with Alzheimer's disease and normal aging.

Authors:  M el-Awar; J T Becker; K M Hammond; R D Nebes; F Boller
Journal:  Arch Neurol       Date:  1987-02

8.  EC array sensor concepts and data.

Authors:  W R Matson; P G Gamache; M F Beal; E D Bird
Journal:  Life Sci       Date:  1987-08-17       Impact factor: 5.037

9.  Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow.

Authors:  A E Taylor; J A Saint-Cyr; A E Lang
Journal:  Brain       Date:  1986-10       Impact factor: 13.501

10.  Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.

Authors:  R Mayeux; Y Stern; M Sano; L Cote; J B Williams
Journal:  Neurology       Date:  1987-07       Impact factor: 9.910

View more
  12 in total

1.  Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.

Authors:  G Finali; M Piccirilli; C Oliani; G L Piccinin
Journal:  Ital J Neurol Sci       Date:  1992-03

Review 2.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

3.  The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression.

Authors:  Jonathan P Roiser; Andrew McLean; Alan D Ogilvie; Andrew D Blackwell; Diane J Bamber; Ian Goodyer; Peter B Jones; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2005-04       Impact factor: 7.853

Review 4.  Psychiatric symptoms in Parkinson's disease.

Authors:  Karen E Anderson; William J Weiner
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

5.  Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype.

Authors:  Nunzio Pomara; Lisa M Willoughby; Audrey Hashim; Henry Sershen; John J Sidtis; Keith Wesnes; David J Greenblatt; Abel Lajtha
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

Review 6.  Toxoplasmosis: Targeting neurotransmitter systems in psychiatric disorders.

Authors:  Tooran Nayeri; Shahabeddin Sarvi; Ahmad Daryani
Journal:  Metab Brain Dis       Date:  2021-09-03       Impact factor: 3.584

7.  Behavioral disturbances in Parkinson's disease.

Authors:  Karen E Anderson
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

8.  Latent toxoplasmosis and human.

Authors:  A Dalimi; A Abdoli
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

Review 9.  The role of estrogen in the treatment of men with schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Tamsyn Van Rheenen; Emily Hayes
Journal:  Int J Endocrinol Metab       Date:  2013-07-01

10.  The double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants.

Authors:  Jing Yang; Xueli Zhang; Yiying Zhu; Emily Lenczowski; Yanli Tian; Jian Yang; Can Zhang; Markus Hardt; Chunhua Qiao; Rudolph E Tanzi; Anna Moore; Hui Ye; Chongzhao Ran
Journal:  Chem Sci       Date:  2017-06-22       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.